시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 반고형제 위탁생산 시장 보고서(2025년)
Semi-Solid Dosage Contract Manufacturing Global Market Report 2025
상품코드 : 1811024
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,369,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,206,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,043,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

세계의 반고형제 위탁생산 시장 규모는 향후 수년간 급성장할 것으로 전망됩니다. 2029년까지 CAGR 10.5%로 확대되어 267억 6,000만 달러로 성장할 것으로 예상됩니다. 예측 기간 동안 예상되는 성장은 피부과 치료에 대한 수요 증가, 만성 피부 질환 유병률 증가, 제네릭 의약품 제조 확대, 위탁생산 비용 효과, 국소 약물 전달에 대한 선호도 증가 등으로 인한 것으로 예측됩니다. 이 기간에 예상되는 주요 동향으로는 제형 기술 진보, 적응 가능한 제조 능력의 필요성, 품질 설계 방법의 채용, 반고형 처리 장치의 기술적 발전, 의약품 개발의 가속화에 대한 수요 증가 등을 들 수 있습니다.

피부 질환의 유병률 증가는 반고형제 위탁생산 시장의 성장을 이끌 것으로 예측됩니다. 피부 질환은 피부의 외관과 기능에 영향을 미치는 질환으로, 자극, 염증, 피부의 비정상적인 증식과 같은 증상을 유발할 수 있습니다. 이러한 피부 질환 증가는 피부 보호 장벽을 손상시키고, 과민증, 알레르기 반응, 만성 문제를 일으키기 쉬워지는 환경 오염의 확대로 인해 크게 발생합니다. 반고형 제제의 위탁생산은 피부 건강을 지원하는 고품질의 정밀하게 배합된 외용 요법을 제조함으로써 이러한 상황을 해결하는 데 중요한 역할을 합니다. 예를 들어 2023년 2월 영국암연구협회(Cancer Research UK)는 영국에서 흑색종 피부암의 연간 평균 이환수가 2023-2025년 약 2년 800명에서 2038-2040년에는 약 2년 6,500명으로 증가할 것으로 예측된다고 보고했습니다. 이 피부 질환 이환율의 급증은 반고형제 위탁생산 시장의 확대에 기여하고 있습니다.

반고형제 위탁생산 시장의 주요 기업은 신시장 진입과 혁신을 추진하기 위해 전략적 투자를 하고 있습니다. 전략적 투자는 기업의 핵심 사업을 강화하고, 미래 성장을 지원하고, 경쟁적 포지셔닝을 강화하는 것을 목표로 하는 장기적인 재무상의 의사결정입니다. 예를 들어, 2025년 3월 미국에 본사를 둔 반고형 제제의 위탁생산 서비스를 제공하는 LGM Pharma는 텍사스주 로젠버그에 있는 제조 시설을 확대하기 위해 600만 달러를 초과하는 투자를 할 것이라고 발표했습니다. 이 구상은 국내의 의약품 제조에 대한 수요 증가에 대응하고, 액제, 현탁제, 반고형제, 좌제 등의 제제의 생산 능력을 증강하는 것을 목적으로 하고 있습니다. 이 확대는 505(b)(2)와 ANDA 프로그램을 포함한 처방약 개발에서 LGM Pharma의 지속적인 성장을 지원합니다. 로젠버그 공장은 FDA 기준과 현재의 적절한 제조 규범을 완벽하게 준수하면서 업그레이드 기간 동안 운영을 계속합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 전략

제36장 부록

JHS
영문 목차

영문목차

Semi-solid dosage contract manufacturing refers to a specialized pharmaceutical service where a third-party manufacturer is hired to produce medicinal formulations with intermediate consistency on behalf of another company. This setup enables the hiring company to outsource the manufacturing process while concentrating on primary functions such as research or marketing.

The primary categories of semi-solid dosage contract manufacturing include topical, transdermal, and oral. Topical semi-solid dosage contract manufacturing entails the external production of products like creams, gels, or ointments that are designed for direct application to the skin. It involves the use of various materials, including synthetic, natural, and bio-based, and caters to companies of all sizes-large, medium, small, and others. Its applications span across areas such as dermatology, pain relief, hormonal treatment, wound healing, eye disorders, and more, serving a range of end users including pharmaceutical and cosmeceutical companies, among others.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

The semi-solid dosage contract manufacturing market research report is one of a series of new reports from The Business Research Company that provides semi-solid dosage contract manufacturing market statistics, including semi-solid dosage contract manufacturing industry global market size, regional shares, competitors with a semi-solid dosage contract manufacturing market share, detailed semi-solid dosage contract manufacturing market segments, market trends and opportunities, and any further data you may need to thrive in the semi-solid dosage contract manufacturing industry. This semi-solid dosage contract manufacturing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The semi-solid dosage contract manufacturing market size has grown rapidly in recent years. It will grow from $16.23 billion in 2024 to $17.97 billion in 2025 at a compound annual growth rate (CAGR) of 10.7%. The growth during the historic period can be credited to the expansion of the geriatric population, rising global healthcare spending, increased demand for hormone replacement therapies, heightened awareness of skincare health, and the development of biologics and biosimilars in topical formulations.

The semi-solid dosage contract manufacturing market size is expected to see rapid growth in the next few years. It will grow to $26.76 billion in 2029 at a compound annual growth rate (CAGR) of 10.5%. The anticipated growth during the forecast period can be attributed to the increasing demand for dermatological treatments, a growing prevalence of chronic skin conditions, the expansion of generic drug manufacturing, the cost-effectiveness of contract manufacturing, and a rising preference for topical drug delivery. Key trends expected during this period include progress in formulation technologies, the need for adaptable manufacturing capacity, the adoption of quality-by-design methodologies, technological advancements in semi-solid processing equipment, and an increasing demand for accelerated drug development.

The increasing prevalence of skin diseases is expected to drive the growth of the semi-solid dosage contract manufacturing market. Skin diseases are conditions that impact the skin's appearance or function and can result in symptoms such as irritation, inflammation, or abnormal skin growths. This rise in skin disorders is largely attributed to growing environmental pollution, which compromises the skin's protective barrier, making it more susceptible to sensitivities, allergic reactions, and chronic issues. Contract manufacturing of semi-solid dosage forms plays a critical role in addressing these conditions by producing high-quality, precisely formulated topical treatments that support skin health. For example, in February 2023, Cancer Research UK reported that the average annual number of melanoma skin cancer cases in the UK is projected to rise from around 20,800 in 2023-2025 to approximately 26,500 by 2038-2040. This surge in skin disease incidence is contributing to the expansion of the semi-solid dosage contract manufacturing market.

Key companies in the semi-solid dosage contract manufacturing market are making strategic investments to enter new markets and drive innovation. Strategic investments are long-term financial decisions that aim to enhance a company's core operations, support future growth, or strengthen competitive positioning. For example, in March 2025, LGM Pharma, a US-based provider of contract manufacturing services for semi-solid dosage forms, announced an investment of over $6 million to expand its manufacturing facility in Rosenberg, Texas. This initiative is intended to increase production capacity for liquid, suspension, semi-solid, and suppository drug formulations in response to rising demand for domestic pharmaceutical manufacturing. The expansion supports LGM Pharma's continued growth in prescription drug development, including 505(b)(2) and ANDA programs. The Rosenberg site will remain operational throughout the upgrade while maintaining full compliance with FDA standards and current good manufacturing practices.

In June 2024, Aterian Investment Partners, a US-based private equity firm, acquired Contract Pharmaceuticals Limited Canada for an undisclosed sum. Following the acquisition, CPL is poised to enter a new phase of development by enhancing its talent, technological infrastructure, and operational capabilities. This acquisition strengthens CPL's ability to provide value and reinforces its position as a reliable global partner for pharmaceutical companies. Contract Pharmaceuticals Limited is a Canada-based company specializing in the contract manufacturing of semi-solid dosage forms.

Major players in the semi-solid dosage contract manufacturing market are Eurofins Scientific SE, The Lubrizol Corporation, Grunenthal, Recipharm AB, Piramal Pharma Solutions Inc., Cambrex Corporation, Sharp Services, ANI Pharmaceuticals, Pierre Fabre SA, Aurigene Pharmaceutical Services Limited, DPT Laboratories Ltd., Douglas Pharmaceuticals Ltd., Mission Pharmacal Co., Pace Analytical Life Sciences LLC, Bora Pharmaceuticals Co. Ltd., Ascendia Pharmaceuticals Inc., Fermion Oy, Ferndale Pharma Group, Sterling Pharmaceutical Services LLC, Aphena Pharma Solutions Inc., Eubioco LLC, LGM Pharma LLC, Madras Pharmaceuticals, Quality CDMO, and Axxelent Pharma Science.

North America was the largest region in the semi-solid dosage contract manufacturing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in semi-solid dosage contract manufacturing report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the semi-solid dosage contract manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The semi-solid dosage contract manufacturing market consists of revenues earned by entities by providing services such as process development, formulation support, analytical method development, and quality control testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The semi-solid dosage contract manufacturing market also includes sales of medicated balms, moisturizing agents, lubricating agents, and skin repair agents. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Semi-Solid Dosage Contract Manufacturing Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on semi-solid dosage contract manufacturing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for semi-solid dosage contract manufacturing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The semi-solid dosage contract manufacturing market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Semi-Solid Dosage Contract Manufacturing Market Characteristics

3. Semi-Solid Dosage Contract Manufacturing Market Trends And Strategies

4. Semi-Solid Dosage Contract Manufacturing Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Semi-Solid Dosage Contract Manufacturing Growth Analysis And Strategic Analysis Framework

6. Semi-Solid Dosage Contract Manufacturing Market Segmentation

7. Semi-Solid Dosage Contract Manufacturing Market Regional And Country Analysis

8. Asia-Pacific Semi-Solid Dosage Contract Manufacturing Market

9. China Semi-Solid Dosage Contract Manufacturing Market

10. India Semi-Solid Dosage Contract Manufacturing Market

11. Japan Semi-Solid Dosage Contract Manufacturing Market

12. Australia Semi-Solid Dosage Contract Manufacturing Market

13. Indonesia Semi-Solid Dosage Contract Manufacturing Market

14. South Korea Semi-Solid Dosage Contract Manufacturing Market

15. Western Europe Semi-Solid Dosage Contract Manufacturing Market

16. UK Semi-Solid Dosage Contract Manufacturing Market

17. Germany Semi-Solid Dosage Contract Manufacturing Market

18. France Semi-Solid Dosage Contract Manufacturing Market

19. Italy Semi-Solid Dosage Contract Manufacturing Market

20. Spain Semi-Solid Dosage Contract Manufacturing Market

21. Eastern Europe Semi-Solid Dosage Contract Manufacturing Market

22. Russia Semi-Solid Dosage Contract Manufacturing Market

23. North America Semi-Solid Dosage Contract Manufacturing Market

24. USA Semi-Solid Dosage Contract Manufacturing Market

25. Canada Semi-Solid Dosage Contract Manufacturing Market

26. South America Semi-Solid Dosage Contract Manufacturing Market

27. Brazil Semi-Solid Dosage Contract Manufacturing Market

28. Middle East Semi-Solid Dosage Contract Manufacturing Market

29. Africa Semi-Solid Dosage Contract Manufacturing Market

30. Semi-Solid Dosage Contract Manufacturing Market Competitive Landscape And Company Profiles

31. Semi-Solid Dosage Contract Manufacturing Market Other Major And Innovative Companies

32. Global Semi-Solid Dosage Contract Manufacturing Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Semi-Solid Dosage Contract Manufacturing Market

34. Recent Developments In The Semi-Solid Dosage Contract Manufacturing Market

35. Semi-Solid Dosage Contract Manufacturing Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기